Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHT Study: Contrave CVOT in Overweight/Obese Patients
NCT01601704Phase 3Terminated
- Sponsor
- Orexigen Therapeutics
- Start
- Jun 2012
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of naltrexone + bupropion in obesity, Overweight, sponsored by Orexigen Therapeutics. Started Jun 2012; status: terminated.
02
Drugs
naltrexone + bupropion
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT01601704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01601704.